In summary, these studies have identified enhanced expression of Cav3.2 as a feature of trastuzumab-resistant breast cancer cells, however, Cav3.2 does not seem to be a driver of trastuzumab-resistance. This evidence concerns the gene CACNA1H and breast cancer.